1. Home
  2. HBIO vs ATNM Comparison

HBIO vs ATNM Comparison

Compare HBIO & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$8.10

Market Cap

26.5M

Sector

Industrials

ML Signal

HOLD

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.41

Market Cap

31.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBIO
ATNM
Founded
1901
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.5M
31.7M
IPO Year
2000
2013

Fundamental Metrics

Financial Performance
Metric
HBIO
ATNM
Price
$8.10
$1.41
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$18.00
$4.50
AVG Volume (30 Days)
20.2K
180.2K
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
14.17
EPS
N/A
0.71
Revenue
$116,176,000.00
$90,000.00
Revenue This Year
$4.77
N/A
Revenue Next Year
$8.55
N/A
P/E Ratio
N/A
$1.73
Revenue Growth
N/A
11.11
52 Week Low
$0.38
$0.74
52 Week High
$8.40
$1.74

Technical Indicators

Market Signals
Indicator
HBIO
ATNM
Relative Strength Index (RSI) 71.44 74.47
Support Level $5.91 $0.98
Resistance Level $8.40 $1.38
Average True Range (ATR) 0.28 0.06
MACD -0.00 0.02
Stochastic Oscillator 73.29 83.78

Price Performance

Historical Comparison
HBIO
ATNM

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

Share on Social Networks: